133406-29-8
133406-29-8 性质
| 沸点 | 329.1±42.0 °C(Predicted) |
|---|---|
| 密度 | 1.674±0.06 g/cm3(Predicted) |
| 储存条件 | Sealed in dry,Store in freezer, under -20°C |
| 溶解度 | 可溶于 DMSO（高达 30 mg/ml）或乙醇（高达 6 mg/ml） |
| 形态 | 固体 |
| 颜色 | 粘黄色 |
| 稳定性 | 自购买之日起，稳定期为 1 年。 其DMSO 或乙醇溶液可在 -20°C 下保存长达 3 个月。 |
133406-29-8 用途与合成方法
IC50: 2.3 μM (AC1)
ST034307 reveals selective inhibition of AC1 and potentiates AC8 activity to a nonsignificant small extent. ST034307 potentiates phorbol 12-myristate 13-acetate (PMA)-stimulated cAMP production by AC2. ST034307 significantly inhibits the forskolin- or isoproterenol-stimulated AC1 activity in HEK cells stably expressing AC1. In contrast, ST034307 has no significant effects in the wild-type HEK cells. ST034307 significantly inhibits the Ca 2+ /calmodulin-stimulated cAMP accumulation in the hippocampal homogenates. ST034307 dose-dependently inhibits both the development and the maintenance of MOR-mediated sensitization of AC1.
ST034307 (0.25 μg) causes a significant relief of CFA-induced inflammatory pain in mice. ST034307 exhibits an estimated median effective dose (E 50 ) value for analgesia of 0.28 μg in the mouse pain model.
133406-29-8 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025-02-08 | HY-101279 | 133406-29-8 | 133406-29-8 | 5mg | 770 |
| 2025-02-08 | HY-101279 | 133406-29-8 | 133406-29-8 | 10mM * 1mLin DMSO | 847 |
